{
  "id": 11594368,
  "title": "Natera president Solomon Moshkevich sells $1.24m in shares",
  "url": "https://urgent.news/2026/10/03/natera-president-solomon-moshkevich-sells-1-24m-in-shares",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-03T03:31:08.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/natera-president-solomon-moshkevich-sells-124m-in-shares-93CH-4930745"
  },
  "original_language": "en",
  "account": "Solomon Moshkevich, Natera's President of Clinical Diagnostics, sold $1.24 million worth of the company's stock on October 1, 2026. The transactions, conducted under a pre-approved trading plan, comprised 2,000 shares purchased at varying prices ranging from $411.62 to $415.0691 per share. Natera's stock has been trading near its 52-week high of $427.47, following a dramatic 145% growth over the past year. Despite this, the stock is currently considered overvalued by InvestingPro research. Moshkevich remains the largest shareholder, owning 106,914 shares of Natera common stock. Natera's recent quarterly report exceeded market expectations, with revenue at $753 million. Management raised its full-year revenue guidance, citing strong performance in key areas. RBC Capital raised its price target for Natera to $460, and Rothschild Redburn assigned a Buy rating and $385 price target, citing the company's leadership in minimal residual disease testing. These factors highlight Natera's significant potential in the market.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}